SKYE Stock Analysis: Buy, Sell, or Hold?
SKYE - Skye Bioscience, Inc. Common Stock
$1.01
0.05 (5.21%)
▲
5d:
+0.0%
30d:
+38.93%
90d:
-36.08%
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Mar 19, 2026
Get Alerted When SKYE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: SKYE shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: SKYE shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: SKYE is currently trading at $1.01, which is considered slightly high relative to its 30-day fair value range of $0.85 to $1.06.
Technical Outlook: Technically, SKYE is in a strong downtrend. Immediate support is located at $0.94, while resistance sits at $1.07. The stock is showing strong short-term momentum, up 5.2% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.25 (+716.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SKYE is in a strong downtrend. Immediate support is located at $0.94, while resistance sits at $1.07. The stock is showing strong short-term momentum, up 5.2% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.25 (+716.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$0.85 -
$1.06
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.1%
All Signals
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.2%)
- BULLISH: Trading 716.8% below Wall St target ($8.25)
Fair Price Analysis
30-Day Fair Range
$0.85 -
$1.06
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$0.94
Resistance Level
$1.07
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-0.87
Wall Street Target
$8.25
(+716.8%)
Last updated: February 02, 2026 3:15 AM ET
Data refreshes hourly during market hours. Next update: 4:15 AM
Data refreshes hourly during market hours. Next update: 4:15 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SKYE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
5Am Partners Vii, Llc
SELL
170449 shares
2025-08-22
Andrew J Schwab
SELL
170449 shares
2025-08-22
5Am Partners Vii, Llc
SELL
60956 shares
2025-08-21
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$66 | 46 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$93 | 59 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$108 | 56 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$34 | 51 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$71 | 60 HOLD |
